Alzinova: What the aducanumab failure means for the prospects of ALZ-101
Research Update
2019-04-04
07:30
A couple of weeks ago, Biogen/Eisai announced the discontinuation of aducanumab programs, including the phase III trials, ENGAGE and EMERGE. In this report, we provide a thorough analysis of what the latest news regarding aducanumab means for Alzinova’s lead candidate, ALZ-101. We factor in a higher development risk post-aducanumab news, which has led to updated valuations.
AH
Anders Hedlund
Disclosures and disclaimers